Superworth

Gilead Sciences forward PE GILD

Share price divided by analysts' consensus earnings for the next twelve months, since 2001.

Today, Oct 23, 2026
17.2×
10-year median
10.5×
Against its 10-year history
89th
percentile: 0 is its lowest day, 100 its highest
10-year range
7.5× to 25.7×
Peer median
18.8×

Gilead Sciences' forward PE is 17.2× as of Oct 23, 2026.

That is above its ten-year median of 10.5×, higher than on 89% of days in the last ten years.

Over that time it ranged from 7.5× in Dec 2020 to 25.7× in Jan 2024.

The median for 8 large drugmakers of a similar size is 18.8×.

Forward PE over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far17.2×14.6×17.2×
202514.5×11.8×15.3×
202412.4×9.7×25.7×
202323.8×11.3×23.8×
202213.0×9.3×13.5×
202111.5×8.3×11.5×
20207.7×7.5×12.0×
20199.9×9.3×10.4×
20188.8×8.8×13.4×
201711.2×8.3×12.2×
20168.3×7.0×8.9×
20158.5×8.4×11.6×
201410.3×9.1×15.7×
201314.5×13.1×27.8×
201218.8×11.1×19.8×
201110.6×9.3×11.1×
20109.2×8.5×13.7×
200912.8×12.6×24.4×
200823.4×18.4×27.8×
200725.7×21.4×26.3×

Against its peers

Companies in Drug Manufacturers - General nearest Gilead Sciences' size, closest first, today.

CompanyForward PE
GILDGilead Sciences17.2×
PFEPfizer10.9×
AMGNAmgen18.6×
BMYBristol-Myers Squibb10.4×
MRKMerck17.5×
ABBVAbbVie19.0×
JNJJohnson & Johnson23.4×
BIIBBiogen19.1×
LLYEli Lilly and33.9×
Peer median18.8×

Where Gilead Sciences ranks

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on Gilead Sciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.